Rose-Hulman faculty, staff lauded for outstanding teaching, scholarship and service
Three Rose-Hulman Institute faculty and staff have been recognized for their efforts in fulfilling hallmarks of the institute's educational mission: personal attention, dedication to student success and quality service, according to a campus news release.
Daniel Chang, associate professor of electrical & computer engineering, received the dean's Outstanding Teacher Award, while Tim Grose, associate professor of China Studies, was presented with the Board of Trustees' Outstanding Scholar Award.
Dale Long, director of media relations and executive editor of Echoes, earned the President's Outstanding Service Award. Employed at Rose-Hulman for 37 years, he is retiring at the end of June.
The trio were recognized at this year's pre-commencement awards May 29 in Hatfield Hall and again Saturday during Rose-Hulman's 147th commencement.
Each award winner consistently has received accolades and appreciation from campus community members, and their respective presenters acknowledged their contributions in making Rose-Hulman "a remarkable place for the world's best undergraduate science, engineering, and mathematics education in an atmosphere of individual attention and support," according to the news release.
Chang, who teaches a range of courses from Introduction to Digital Systems to Advanced Computer Architecture, has been praised by students for his ability to clearly explain complex technical material through engaging storytelling, humor, and an inclusive classroom environment.
Known for his 'never off-topic' policy that encourages genuine curiosity, Chang structures his courses with intention, clarity, and enthusiasm. Students consistently describe his teaching style as 'incredibly enthusiastic,' 'genuine,' and 'fun,' often noting that his own passion for teaching helps them find joy in learning even the most challenging concepts.
Grose was recognized for his consistent and high-impact scholarship in the field of China Studies, with a particular focus on the Uyghur ethnic minority and issues of identity, policy, and repression within China.
His widely cited 2019 book, 'Negotiating Inseparability in China: The Xinjiang Class and the Dynamics of Uyghur Ethno-National Identity,' received the Central Eurasian Studies Society Book Prize in the Social Sciences. A second book, 'Settling Xinjiang: China's Colonial Project,' is currently under review by University of Washington Press.
For 37 years, Long has celebrated the people and progress of Rose-Hulman, documenting student triumphs, faculty achievements, and alumni legacies on campus and across the country.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Rose-Hulman faculty, staff lauded for outstanding teaching, scholarship and service
Three Rose-Hulman Institute faculty and staff have been recognized for their efforts in fulfilling hallmarks of the institute's educational mission: personal attention, dedication to student success and quality service, according to a campus news release. Daniel Chang, associate professor of electrical & computer engineering, received the dean's Outstanding Teacher Award, while Tim Grose, associate professor of China Studies, was presented with the Board of Trustees' Outstanding Scholar Award. Dale Long, director of media relations and executive editor of Echoes, earned the President's Outstanding Service Award. Employed at Rose-Hulman for 37 years, he is retiring at the end of June. The trio were recognized at this year's pre-commencement awards May 29 in Hatfield Hall and again Saturday during Rose-Hulman's 147th commencement. Each award winner consistently has received accolades and appreciation from campus community members, and their respective presenters acknowledged their contributions in making Rose-Hulman "a remarkable place for the world's best undergraduate science, engineering, and mathematics education in an atmosphere of individual attention and support," according to the news release. Chang, who teaches a range of courses from Introduction to Digital Systems to Advanced Computer Architecture, has been praised by students for his ability to clearly explain complex technical material through engaging storytelling, humor, and an inclusive classroom environment. Known for his 'never off-topic' policy that encourages genuine curiosity, Chang structures his courses with intention, clarity, and enthusiasm. Students consistently describe his teaching style as 'incredibly enthusiastic,' 'genuine,' and 'fun,' often noting that his own passion for teaching helps them find joy in learning even the most challenging concepts. Grose was recognized for his consistent and high-impact scholarship in the field of China Studies, with a particular focus on the Uyghur ethnic minority and issues of identity, policy, and repression within China. His widely cited 2019 book, 'Negotiating Inseparability in China: The Xinjiang Class and the Dynamics of Uyghur Ethno-National Identity,' received the Central Eurasian Studies Society Book Prize in the Social Sciences. A second book, 'Settling Xinjiang: China's Colonial Project,' is currently under review by University of Washington Press. For 37 years, Long has celebrated the people and progress of Rose-Hulman, documenting student triumphs, faculty achievements, and alumni legacies on campus and across the country.
Yahoo
15 hours ago
- Yahoo
Terre Haute graduate honored during Rose-Hulman commencement
Alisha Mastakar of Terre Haute was among Rose-Hulman Institute of Technology graduates to receive special honors during commencement ceremonies Saturday. Mastakar, a nanoengineering and optical engineering graduate, received the Herman A. Moench Distinguished Senior Commendation for distinguishing herself as a commendable influence on members of the Rose-Hulman community. Mastakar, who earned summa cum laude academic graduation honors, was a Noblitt Scholar and served the campus community and Indiana in a variety of ways. Mastakar's post-graduation plans include pursuing a doctorate degree at Rochester Institute of Technology. Computer engineering graduate Vineet Ranade, of Mountain View, Calif., received the John T. Royse Award for being considered the most outstanding graduate, in the opinion of Rose-Hulman's faculty and staff, based upon academic achievement, student leadership, participation in co-curricular activities, and general campus citizenship. Ranade embodied all aspects of the Royse Award —academic achievement, student leadership, participation in co-curricular activities, and general campus citizenship —while finding success in everything he did while attending Rose-Hulman, said Erik Hayes, vice president of student affairs and dean of students. In addition, a record 15 students earned Heminway Gold Medals for attaining the highest academic achievement (4.0 grade-point average) during their Rose-Hulman careers. Ranade was engaged in several different research opportunities, which included evolvable hardware and investigating the merits of social networking for Bangladeshi farmers. Outside of the classroom, he excelled as a student-athlete, twice qualifying for the NCAA Division III swimming and division championships, winning multiple Heartland Collegiate Athletic Conference swimming event titles and establishing numerous school and conference records. Joining Ranade as this year's Heminway Gold Medal recipients were Salik Ahmad, Kyle Asbury, Ariadna Duvall, Calvin Hamilton, Natalie Hannum, Kaylee Lane, Benjamin Lyons, Henry Nunns, Justin Roberts, Joshua Schrock, Mark Serdinak, Ellen Shales, Blaise Swartwood, and Isaac Towne.
Yahoo
a day ago
- Yahoo
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought forward more than a dozen programs from discovery into clinical development, and he has developed multiple pioneering approved medicines such as Sotyktu, Stelara, and Tremfya. 'Dr. Rose joins the Nkarta team at a critical threshold as we discover the power of our NK cell platform to treat autoimmune diseases,' said Paul J. Hastings, CEO of Nkarta. 'He is an enterprise leader with a deep clinical background in rheumatology and immunology that's ideally suited to maximize the potential of our allogeneic NK cell platform. Shawn's proven track record as an expert clinician gives me full confidence that he will hit the ground running on day one and meaningfully advance our work in the clinic.' Dr. Rose most recently served as Chief Development Officer, Immunology, at Vividion Therapeutics, working to expand their portfolio by advancing previously undruggable targets in immunology. He also served as interim CMO and Head of Clinical Development at Magenta Therapeutics, working on cell-based therapeutic approaches for patients with cancer, genetic disorders and immune-mediated inflammatory diseases. Dr. Rose also held multiple clinical and development leadership roles at Annexon Biosciences, Janssen Pharmaceuticals, and Bristol-Myers Squibb. He did his postdoctoral research training and clinical training in Internal Medicine and Rheumatology at the Northwestern University Feinberg School of Medicine. 'I am thrilled to join Nkarta to advance innovative cell therapies for patients,' said Dr. Rose. 'I strongly believe that Nkarta's allogeneic NK cell platform has the potential to be a transformational approach for patients with immune-mediated inflammatory disease. I look forward to working closely with Paul and the broader Nkarta team on developing more treatment options for patients.' During the transition, Dr. Rose will work with Dr. Shook, who will remain on as a consultant through July 11. 'Dave was an early pioneer of NK cell therapy while working under Nkarta's scientific founder, Dario Campana, at St. Jude Children's Research Hospital, and he has tirelessly pursued options that were more convenient for patients with safety utmost in mind,' Hastings said. 'Dave has devoted much of his career to make important contributions to the advancement of natural killer cell therapy, leading our early clinical work in cancer and overseeing key aspects of our strategic shift into a new disease area with agility and flexibility. But Dave is a dedicated oncologist, and he has decided to return to the field he loves. He is a fearless advocate for patients and their well-being and a very good friend who will be missed.' About NKX019NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Nkarta is evaluating NKX019 in multiple autoimmune conditions. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at Cautionary Note on Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," 'plans,' 'potential,' "projects,' 'would' and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, statements concerning Nkarta's expectations regarding any or all of the following: Nkarta's position, plans, strategies, and timelines for the continued and future clinical development and commercial potential of NKX019 (including the future availability and disclosure of clinical data and other updates from Nkarta's clinical trials). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Nkarta's limited operating history and historical losses; Nkarta's lack of any products approved for sale and its ability to achieve profitability; the risk that the results of preclinical studies and early-stage clinical trials may not be predictive of future results; Nkarta's ability to raise additional funding to complete the development and any commercialization of its product candidates; Nkarta's dependence on the clinical success of NKX019; that Nkarta may be delayed in initiating, enrolling patients in or completing its clinical trials; competition from third parties that are developing products for similar uses; Nkarta's ability to obtain, maintain and protect its intellectual property; Nkarta's dependence on third parties in connection with manufacturing, clinical trials and pre-clinical studies; the complexity of the manufacturing process for CAR NK cell therapies; and the success of Nkarta's recent (and any future) cost containment measures. These and other risks and uncertainties are described more fully in Nkarta's filings with the Securities and Exchange Commission ('SEC'), including the 'Risk Factors' section of Nkarta's Annual Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025, and Nkarta's other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Nkarta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Nkarta Media/Investor Contact:Nadir MahmoodNkarta, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
